Metagenomi
About: Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
Employees: 202
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
131% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 13
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
58% more capital invested
Capital invested by funds: $24.5M [Q3] → $38.7M (+$14.2M) [Q4]
15% more funds holding
Funds holding: 66 [Q3] → 76 (+10) [Q4]
1.55% less ownership
Funds ownership: 30.22% [Q3] → 28.67% (-1.55%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$20
1,404%
upside
Avg. target
$20
1,404%
upside
High target
$20
1,404%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Yanan Zhu 11% 1-year accuracy 1 / 9 met price target | 1,404%upside $20 | Overweight Maintained | 18 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months
Neutral
GlobeNewsWire
2 weeks ago
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system with activity in human cells Expression of the compact CAST system from a single 'all-in-one' mRNA design represents a first-in-class approach to simplifying delivery for therapeutic applications Additional updates on further advancements in novel large gene integration technology anticipated in 2025 EMERYVILLE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced a publication in the journal Nature Communications describing its novel, compact CAST system for large, targeted gene integration into the human genome.
Neutral
GlobeNewsWire
1 month ago
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
EMERYVILLE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Brian C. Thomas, PhD, CEO and founder of Metagenomi, will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 1:10-1:40 p.m. ET in Boston. The company will host one-on-one investor meetings at the conference.
Neutral
GlobeNewsWire
2 months ago
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing Approach On Track for One to Two Development Candidate Nominations in 2025 from Wave 1 Ionis Collaboration Programs Focusing on Cardiometabolic Indications Cash Runway Anticipated to Support Operating Plans into 2027 EMERYVILLE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today provided updates on the successful achievement of critical milestones across its therapeutic development programs and technology platforms in 2024 and anticipated milestones for 2025 and 2026.
Neutral
GlobeNewsWire
2 months ago
Metagenomi Announces New Appointment to its Board of Directors
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi's Board of Directors, serving on Metagenomi's Audit and Compensation committees, effective January 27, 2025.
Neutral
GlobeNewsWire
2 months ago
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Brian C. Thomas, PhD, CEO and founder of Metagenomi, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 4:30 p.m. PT in San Francisco.
Neutral
GlobeNewsWire
3 months ago
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells EMERYVILLE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a talk titled “Specific and efficient genome editing with metagenomics-derived tools for in vivo and ex vivo therapeutic applications” at the Nature Conference: RNA at the Bench and Bedside IV.
Neutral
GlobeNewsWire
3 months ago
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up
Neutral
Accesswire
4 months ago
Metagenomi, Inc. Class Action: Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024 - MGX
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113560&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
4 months ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Metagenomi, Inc. (MGX) Shareholders
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113547&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™